NCT00063999 · MORE INFO

Limitations, agreements, and source contact

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer · Source last updated 2021-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restriction Type: LTE60
restrictive Agreement: true

limitations And Caveats

description: Eligibility for this study was expanded from measurable, stage 3 or stage 4 or recurrent disease to include non-measurable, stage 4 or recurrent disease and then to include non-measurable stage 3 disease.

point Of Contact

email: lgedeon@gogstats.org
organization: NRG Oncology
phone: 716-545-8321
title: Linda Gedeon for Virginia Filiaci, PhD.

Complete source fields

certain Agreement

pi Sponsor Employee: false
restriction Type: LTE60
restrictive Agreement: true

limitations And Caveats

description: Eligibility for this study was expanded from measurable, stage 3 or stage 4 or recurrent disease to include non-measurable, stage 4 or recurrent disease and then to include non-measurable stage 3 disease.

point Of Contact

email: lgedeon@gogstats.org
organization: NRG Oncology
phone: 716-545-8321
title: Linda Gedeon for Virginia Filiaci, PhD.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice